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ABSTRACT 
There is a lack of good CXCR4 inhibitors that treat cancer cell metastasis and 
autoimmune diseases without serious drawbacks. AMD3100 and WZ811 are the CXCR4 
antagonists that were the initial structural basis for our new potential therapeutics. Molecular 
modeling and the principles of drug discovery and design were used to plan the synthesis of the 
compounds presented here. These compounds were synthesized via reductive amination, and 
then purified via flash column chromatography or preparatory thin layer chromatography. The 
small molecules were then characterized via melting point, high resolution MS, 13C, and 1H 
NMR spectroscopy. The Matrigel invasion assay and binding affinity assay were used to screen 
the potency of the compounds. Compounds that showed high potency in these assays were then 
subjected to the carrageenan mouse paw edema test. Two lead compounds have emerged as 
candidates for further testing (2v, and 2a).  
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1 INTRODUCTION: THE RATIONALE FOR SYNTHESIZING SMALL 
MOLECULES AS CHEMOKINE RECEPTOR ANTAGONISTS  
1.1 Review of Chemokines 
Chemokines (like CXCL12) are small proteins that bind to seven-transmembrane G-
protein coupled receptors (GPCRs) like CXCR4, which was previously known as CD184, 
LESTR1 and fusin.2 GPCRs are a large family of chemokine receptors that can be found on the 
cell surface and are involved in signaling for the immune and inflammatory response throughout 
the cell.3 Chemokines are shown to be chemoattractants for various leukocytes, which is the 
vehicle for immune and inflammatory response.2, 4 Chemokines are further classified into four 
subfamilies based on the placement of the conserved cysteine groups on the amino N-terminus: 
CC, CXC, C, and CX3C.
5 The name chemokine comes from the word chemotaxis, which refers 
to compounds that attract other chemicals within the body.5a Cytokines are small proteins 
involved in the immune response, and under this classification, there are subcategories of 
proteins. These subcategories include lymphokines, interleukins, monokines, and chemokines.5a 
There are chemokines that are promiscuous,6 viral,7 specific,8 and shared.6 Promiscuous 
chemokines have multiple binding partners; for example, CXCL12 binds to both CXCR4 and 
CXCR7.9 Viral chemokines are chemokines that exist within viral organisms. Specific 
chemokines are specific to only one binding partner. Shared chemokines may only bind within 
one family, but can have multiple binding partners within that family. CXCL12 and CXCR4 
control various processes including cell migration during the immune response, but such a 
complex process has also allowed the chemokine/chemokine receptor axis to contribute to the 
progression of various ailments such as HIV,2 cancer,10 and auto-immune diseases (Figure 1).2, 11 
2 
The large increase in the number of known chemokine receptors and their ligands has allowed 
for the synthesis of new antagonists to treat the various ailments using this signaling pathway.12  
In this work, we focus on the interaction between the chemokine receptor CXCR4 and its 
chemokine CXCL12. The structure of CXCR4 consists of seven transmembrane helixes. Also, 
there are three extracellular loops (ECL1-3), and two disulfide bridges.13 Cys2747.25 found on 
helix VII forms a disulfide bond with Cys28 in the N-terminal, Cys1093.25forms a second 
disulfide bond with Cys186 on ECL2, which shape the binding pocket and are important in 
ligand binding.13-14  
The globular domain of the chemokine CXCL12 is believed to bind to the CXCR4 N-
terminus, and the three extracellular loops, which forms an interaction site that gives it affinity 
and specificity via a conformational change.13, 15 The N-terminus of the CXCL12 chemokine is 
then thought to enter the helical bundle of the chemokine receptor shown in green on CXCR4 to 
activate the majority of receptor signaling.16 Thus, there is a two site binding model for the 
chemokine CXCL12 binding to the chemokine receptor CXCR4.16a However, blocking the 
CXCL12 N-terminus from binding to the helical bundle of CXCR4 with a small molecule 
antagonist does not completely block activation.15 The CXCL12 globular domain is still able to 
bind to the CXCR4 N-terminus and three extracellular loops at the top of the protein.17 Some 
activity is still required for important biological processes like the inflammatory and immune 
response. Therefore, an inhibitor that completely blocks the CXCL12 CXCR4 axis is not an 
acceptable outcome.  
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Figure 1: Diagram of various processes regulated by CXCR4. Adapted with permission from the 
American Chemical Society. Choi, W.-T.; Duggineni, S.; Xu, Y.; Huang, Z.; An, J., Drug 
Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4). Journal of Medicinal 
Chemistry 2011, 55 (3), 977-994.18 
CXCR4 is integral to survival. Knockout mice without CXCR4 died in utero due to a 
heart defect, defective vascular development, defective cerebellar neuronal layer formation, and 
defects in haematopoiesis.19 The CXCL12-CXCR4 binding axis initiates a cascade of 
downstream pathways (Figure 2) that include: calcium signaling via the release of intracellular 
calcium,20 mobilization of inflammatory and immune cells,20a promotion of cell survival,21 stem 
cell migration,22 gene transcription,11b and cell adhesion.11b, 23 Through these pathways, CXCR4 
activation is responsible for the processes involved in HIV-1 entry,24 autoimmune and 
inflammatory diseases,25 and tumor cell metastasis.26 Below is a brief description of the role of 
the CXCL12-CXCR4 axis in HIV-1, autoimmune and inflammatory diseases, and cancer 
metastasis.  
CXCL12 
WZ811 
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1.2 CXCR4 and HIV-1 
CXCR4 is an entry cofactor for T-cell line tropic (TCL) HIV-1 along with CCR5 and 
CD4.2 CXCR4 is involved in the later stages of HIV-1 progression as a coreceptor. It has been 
shown that even at low levels, CXCR4 still allows for significant chemotaxis of naïve T cells 
like CD4 but levels of CXCR4 rise early on during HIV-1 invasion.27 The initial invasion of T-
tropic HIV-1 called cell fusion was shown to require both CXCR4 and CD4, while M-tropic 
strains of HIV used a different chemokine receptor.24b It was later shown that there exist CD4 
independent strains of HIV-1 that also utilize CXCR4.28  
1.3 CXCR4 and autoimmune diseases 
One of the main hallmarks of Rheumatoid arthritis (RA) is activated T cells in the sera 
and synovial tissue and fluids of the affected region.29 Mature T cells have been shown to more 
easily migrate to these regions in RA sufferers.30 CXCR4 was linked to CD4+ memory T cell 
accumulation in these regions, and it was shown that IL-15, which was produced as a function of 
RA, increased CXCR4 expression.4 Also, CXCL12 stimulates the migration of CD4+ T cells, 
and inhibits the apoptosis of T cells.4 Transforming growth factor beta isoforms found within RA 
synovial fluid amplifies the expression of CXCR4, while CXCL12 allows for the retention of the 
T cells.31 Of note, mice given a CXCR4 antagonist showed reduced T cell accumulation in RA 
areas, which validates our targeting this chemokine receptor in treating inflammatory diseases.32  
Studies of inflammatory bowel diseases (IBD), which include Crohn’s disease (CD), and 
ulcerative colitis (UC) have reported increased levels of CXCR4 present on cells in the affected 
region.33 Lung neutrophils attracted to the lung in the case of lung damage via the immune 
response have the potential to induce acute lung injury (ALI), and lipopolysaccharide (LPS)-
induced lung injury.34 The problems with the immune response in ALI and LPS is that in the 
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later stages of these diseases the CXCR4-CXCL12 pathway promotes the migration and 
retention of neutrophils, and also protects them from death, which promotes the inflammatory 
response.34-35 There was an increase in the expression of CXCL12 and CXCR4 due to LPS and 
ALI.34-35 The recruitment of various immune cells to these areas of injury or inflammation is 
required for host defense, however excess activation and recruitment of these cells leads to these 
inflammatory and autoimmune diseases.  
1.4 CXCR4 and cancer cell metastasis 
CXCR4 is just one of many G protein-coupled receptors found within the body, but 
CXCR4 is of note because of its role in cancer cell invasion and metastasis, proliferation, and 
angiogenesis.11b Cancer cell invasion and metastasis are the processes by which tumor cells 
invade surrounding tissues to grow larger, and various regions far from the original tumor 
respectively.36 CXCR4 is highly expressed on many cancer cells including breast(Figure 2)37, 
lung,37-38 and prostate.39 In addition, organs and tissues such as the bone marrow,40 lymph 
node,41 lung,37 and liver37 have high amounts of  CXCL12 that promote the migration of cancer 
cells that express CXCR4 (Figure 2). Research has shown that blocking the CXCL12-CXCR4 
axis with anti-CXCR4 antibodies can reduce migration of breast cancer cells to the lymph nodes 
and lungs of mice.37 Also, the use of interfering RNA to silence the CXCR4 gene inhibits breast 
cancer metastasis in mice (Figure 3).42 Further methods of inhibiting metastasis were explored by 
using the peptide TN14003 as a CXCR4 antagonist, the results of the inhibition can be seen in 
Figure 4.43 
ErbB2 (tyrosine kinase HER2), which is overexpressed in certain cancers was shown to 
increase CXCR4 expression by assisting in synthesizing more CXCR4, and slowing the 
6 
degradation of CXCR4.44 ErbB2 was also shown to be required for invasion, and metastasis in 
specific types of cancer.44  
 
 
Figure 2: Quantity of CXCR4 present in breast cancer cells, and CXCL12 present in 
common metastasis sites. Adapted by permission from Macmillan Publishers Ltd. Muller, A.; 
Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, 
W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A., Involvement of 
chemokine receptors in breast cancer metastasis. Nature 2001, 410 (6824), 50-56.37 
CXCR4 SDF-1(CXCL12) 
Lymph node 
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Bone marrow 
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Figure 3: Image of the effect of siRNA blocking CXCR4 function on metastasis, and the 
control. Adapted by permission from AACR Publications. Liang, Z.; Yoon, Y.; Votaw, J.; 
Goodman, M. M.; Williams, L.; Shim, H., Silencing of CXCR4 Blocks Breast Cancer Metastasis. 
Cancer research 2005, 65 (3), 967-971.42 
 
Figure 4: Image of the effect of TN14003 blocking CXCR4 on metastasis, and the control. 
Adapted by permission from AACR Publications. Liang, Z.; Wu, T.; Lou, H.; Yu, X.; Taichman, 
R. S.; Lau, S. K.; Nie, S.; Umbreit, J.; Shim, H., Inhibition of Breast Cancer Metastasis by 
Selective Synthetic Polypeptide against CXCR4. Cancer Research 2004, 64 (12), 4302-4308.43 
1.5 Antagonists of CXCR4 
There are many routes that chemists can take to synthesize CXCR4-CXCL12 pathway 
antagonists. One route is to generate synthetically and modularly modified (SMM) chemokines 
Control Treated 
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from the natural ligands, which in our case would be CXCL12.45 These unnatural chemokines 
may inhibit diseases that utilize CXCR4 as a point of entry, but some of these unnatural 
chemokines would have a lower binding affinity than CXCL12, which would allow one to target 
only the disease without significant side effects.45-46 There are also drugs that are made to mimic 
the structure of proteins found in diseases that bind to an active site (CXCR4) like in the case of 
the peptide ALX40-4C (Figure 5), which inhibits HIV-1 infection.46-47 Another route is to take 
existing, or tentative treatments and modify their structure to obtain better activities like the 
CXCR4 peptide based antagonist T22 being used as a basis for T140 (Figure 5).48  
Peptides are an important class of CXCR4 antagonists. One such peptide, T140 (Figure 
5) is a 14-residue peptide whose residues Arg2, Nal3, Tyr5, and Arg14 were essential to its 
activity was elucidated using an alanine scanning study.49 Structure activity relationship (SAR) 
studies of a known pharmacophore resulted in the development of cyclic pentapeptides like 
FC13150(Figure 5), which led to additional peptide CXCR4 antagonists including T2249 and 
TN14003 (Figure 5).51 From SAR and conformational studies of cyclic pentapeptide based 
CXCR4 antagonists, indole (Figure 6) derivatives were designed and synthesized.52 The SAR 
studies of these cyclic pentapeptide derivatives revealed that a phenyl group, one or two 
guanidino groups, and a phenol group - if only one guanidino was present – were required for 
CXCR4 antagonistic activity.52  
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Figure 5: Structure of various peptide CXCR4 antagonists. 
 
Although there are peptides that are potent CXCR4 antagonists, their major flaw is poor 
oral bioavailability. Therefore, researchers pursued the synthesis of small molecules that can 
overcome this challenge. Bicyclams and their derivatives represent the first class of small 
molecule CXCR4 antagonists. The most widely known bicyclam is AMD3100, (Figure 6) which 
was found to be effective against HIV-1 by binding to CXCR4.53 AMD3100 has several 
drawbacks including poor bioavailability and cardiotoxicity.54 However, AMD3100 has since 
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been FDA approved for one time use for stem cell recruitment in cancer patients.55 Other analogs 
of AMD3100 were synthesized and determined that some of the nitrogens on AMD3100 were 
redundant, and that the overall charge at physiological pH does not directly affect CXCR4 
antagonism.56 To improve the characteristics of AMD3100, non-cyclam derivatives such as 
AMD070 (Figure 6) that is a potent orally available CXCR4 antagonist against HIV were 
discovered.57 This class of drugs was further examined and yielded IT1t (Figure 6) after library 
screening.58  
Tetrahydroquinoline based CXCR4 antagonists were first explored utilizing the lead 
AMD070 (Figure 6).57 One group later modified these tetrahydroquinolines with various rings 
that our group is trying to utilize as the core structure59. Further modifications involved 
constraining the ring60, and the replacement of benzimidazole to discover alternative ring 
systems.61 WZ811 (Figure 6) is a lead compound that was synthesized from a series of SAR 
studies starting with the removal of the bicyclam rings of AMD3100.62 It was learned that the 
central aromatic ring is critical for binding, and the central phenyl ring and the nitrogen of the 
linker should only be one carbon apart.62 From their terminal phenyl rings electron donating 
substituents at the para position had lower EC50 values than electron withdrawing substituents 
while either electron withdrawing or electron donating substituents had no discernible trend.62 
The addition of a second nitrogen to the terminal aromatic rings on WZ811 yielded MSX122 
(Figure 6). 54b Many more potential CXCR4 antagonists were synthesized using the structure of 
WZ811, and AMD3100 as a basis for modification.63 An initial study done on guanidine based 
CXCR4 antagonists yielded positive results that merited further study, particularly of 
phenylguanides (Figure 6).64 Library screening using structural modeling of CXCR4 indicated 
that some quinolines (Figure 6) could be CXCR4 antagonists.65 A library screening and then 
11 
modification of the lead compound yielded KRH1636 66, further optimization yielded 
KRH395567 (Figure 6). SAR studies of KRH1636 were done assist in the further development of 
this class of compounds.68 Patents of compounds containing spiro-bonded cyclic groups69, and 
pyrimidines70 (Figure 6) were filed as CXCR4 antagonists as well.  
12 
 
Figure 6: Small molecule CXCR4 antagonists. 
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1.6 Design and Methodology of Drug Discovery 
Drug modification is a field of medicinal chemistry that alters the chemical makeup of 
known and potential therapeutics to make it a more effective treatment. Homologation is a 
modification where carbon chains can be lengthened to one, five, or nine to allow the compound 
entry into the cell membrane.71 The downside to homologation is that the increase in lipophilicity 
may prevent it from being water soluble71. Chain branching is another modification that adds 
branching to carbon chains.71 The branching can potentially prevent it from binding to the target 
receptor or allow it to bind better.71 Ring chain transformations allow for more stability, increase 
lipophilicity, and lock the structure in place.71 Bioisosterism is the replacement of various 
substituents with groups that have been found to have similar physicochemical properties.72 
Modifications may create changes in conformation, size, shape, and hydrogen bonding that are 
all structural effects.71 Absorption, transport, excretion of the compound, lipophilicity, 
hydrophilicity, pKa, and hydrogen bonding are a part of pharmacokinetic effects.71 Blocking, 
aiding metabolism, chemical reactivity, and toxicity are metabolism effects.71 Finally, changes to 
receptor binding interactions are the result of various modifications.71  
The cytoplasm is an aqueous environment, but the cell membrane is a lipophilic 
environment. When pH and the pKa are the same 50 % of the drug is ionized, and 50 % is 
neutral. Therefore, when the compound enters the cell only the neutral compound can enter, and 
the compound in the cell becomes 50 % ionized and 50 % neutral.71 The pH inside and outside 
the membrane will affect the desired pKa of the compound.71 As for modifications, electron 
withdrawing groups will lower the pKa, and electron donating groups will raise the pKa. This 
means that electron withdrawing groups will make acids more ionizable and bases less ionizable. 
Electron donating groups will make bases more ionizable and acids less ionizable.  
14 
 The rule of five is a list of five properties that give a greater than 90 % chance of 
poor oral absorption or bioavailability if two or more of these properties are present.71, 73 These 
properties include a compound with a molecular weight no more than 500 g/mol, a log P no 
greater than five, no more than five hydrogen bond donors expressed as the sum of -OH and -NH 
groups, and no more than 10 hydrogen bond acceptors expressed as the sum of N and O atoms73. 
Silverman expresses that three hydrogen bond donors and six hydrogen bond acceptors should be 
the upper limit.71 Veber and coworkers found that reduced flexibility (10 or fewer rotatable 
bonds), and a low polar surface area (less than or equal to 140 angstroms squared), a total 
hydrogen bond count less than or equal to a total of 12 donors and acceptors are important 
predictors of good oral bioavailability independent of molecular weight.74 Ajay and coworkers 
developed screening criteria that found that if the molecular weight, degree of branching, number 
of rotatable bonds, or the number of hydrogen bond acceptors were increased the compound will 
be less likely to be central nervous system active.75 In contrast, if the aromatic density, number 
of hydrogen bond donors, or log P were increased it would be more likely to be active in the 
central nervous system.75  
In this thesis, we detail the methods, and design of potential CXCR4 antagonists. The 
design of these antagonists was based on AMD3100 and WZ811, which are potent CXCR4 
antagonists.63a AMD3100 has also shown that inhibition of CXCR4 can help restore the immune 
system after chemotherapy by dispersing hematopoietic stem cells from the bone marrow.18, 76 
AMD3100 has been shown to be useful for one-time use, but clinical trials resulted in patients 
exhibiting cardiotoxic side effects.77 AMD3100 and WZ811 also have poor bioavailability, 
which drives the need for better CXCR4 antagonists.18, 63a Attempts have been made at altering 
the substituents around the central phenyl ring of WZ811. Additional SAR studies also show that 
15 
an aromatic central ring is required for its activity. Our group has been focused on substituting 
the central phenyl ring with other heterocyclic aromatic rings such as pyridine rings78, furans, 
and pyrazine. This thesis work will focus on using a Thiophene ring (Figure 7) as the core while 
altering the substituents.62 The synthesized compounds were subjected to a Matrigel invasion 
assay and a binding affinity assay. These two biological assays quantified how well the 
antagonist blocks the receptor, and the quantity of the antagonist required to effectively bind to 
the receptor, respectively.79 Carrageenan paw edema studies were then conducted with the most 
potent compounds according to the assay results. The lab of Dr. Hyunsuk Shim at Emory 
University School of Medicine conducted the biological work.  
 
Figure 7: structure of previous CXCR4 antagonists (AMD3100, and WZ811), and the 
structure of potential CXCR4 antagonists based on altering its central core and substituents. 
2     DISCUSSION 
2.1 Chemistry 
The Thiophene analogs were synthesized using reductive amination procedures of 
Thiophene-2,5-dicarboxaldehyde with the corresponding primary or secondary amine. Three 
16 
different methods for the reductive amination procedure were employed depending on the 
primary or secondary amine being used.  
Method A involved the use of acetic acid as a catalyst and NaBH(OAc)3 as the reducing 
agent (Yield 3 – 26 %). With Method B, the amine and Thiophene-2,5-dicarboxaldehyde are first 
reacted at room temperature to form the imine, then NaBH4 is used to reduce the imine to the 
final amine compound (Yield 6 – 20 %). Method C was the same as Method B, however the 
dicarboxaldehyde and the amine are heated under reflux conditions to promote a reaction. The 
reactions that required the use of reflux conditions used secondary amines that were less reactive 
like Piperidine that did not have an aromatic group. Amines that had a higher pKa and were more 
sterically hindered than other amines like aniline required reflux conditions to go to completion. 
However, some reactions did not go to completion even after using reflux conditions. Method B 
was used to try to get a better yield by forming the imine first and then adding the reducing agent 
to prevent the reduction of the aldehyde to an alcohol.  
17 
 
Scheme 1: Synthesis of 2,5-thiophene compounds 2a-x. These products were synthesized 
via two different procedures. This list shows the substituents that have been synthesized with this 
core using aniline (2a-s), and cyclic amino (2t-u) benzylamine (2v-x) derivatives.  
 
2.2 Biology 
2.2.1 Binding Assay 
The binding affinity assay was used as the initial assay to screen potential CXCR4 
antagonists (Figure 8). The MDA-MB-231 breast cancer cells were incubated with the 
compounds at a concentration of 1, 10, 100, and 1000 nM. The cells were then incubated with a 
biotinylated peptide TN14003 (a known CXCR4 inhibitor), followed by streptavidin-rhodamine. 
The fluorescence of the cells was measured to obtain effective concentration (EC), which is the 
lowest concentration where there is a significant reduction in fluorescence compared to the 
positive control. The binding affinity assay is the first assay used to screen potential antagonists, 
and eleven out of the twenty-four compounds synthesized went on to the Matrigel invasion assay 
by having an EC of 100 nM or less.   
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Some categories of compounds show promise in the binding assay (Table 1), and are 
features that will be repeated in other analogs to synthesize better potential antagonists. This 
includes benzene groups with substituents on the ortho and para position over substituents on the 
meta position. A phenyl ring with no substituents did well in the binding affinity assay (2a). The 
2-Chloro, 3-Chloro, and 4-Chloro substituted anilines all did well (2k, 2l, and 2m). 2-Methyl, 4-
Methyl, 2-Methoxy, and 4-Methoxy substituted anilines also did well in the assay (2b, 2d, 2n, 
and 2p). Only 3-Trifluoromethylaniline, and 4-Trifluoromethylbenzylamine (2r, and 2v) did well 
out of all the Fluorine substituted compounds. Thiomorpholine was a compound that while 
structurally similar to morpholine did well in the binding affinity assay (2u).  
 
 
Figure 8: Reduction of inflammation observed for selected compounds. 2i had an EC of 
10 nM, 2c had an EC of 100 nM, and 2r had an EC of 1000 nM. Adapted by Permission from 
Elsevier. Gaines, T.; Camp, D.; Bai, R.; Liang, Z.; Yoon, Y.; Shim, H.; Mooring, S. R., Synthesis 
and evaluation of 2,5 and 2,6 pyridine-based CXCR4 inhibitors. Bioorganic & Medicinal 
Chemistry 2016, 24 (21), 5052-5060.80 
2b 
  
  
2d 
  
  
2e 
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2.2.2 Matrigel Invasion Assay 
The Matrigel invasion assay was used to indicate if the potential antagonists can block 
CXCR4/CXCL12 mediated chemotaxis and invasion. Compounds that had an effective 
concentration of 100 nM or better in the binding assays went on to this Matrigel invasion assay. 
MDA-MB-231 cells that have been incubated in 100 nM concentrations of the analogs were 
placed in the top of a special two chambered apparatus, and CXCL12 was placed at the bottom 
as a chemoattractant. In between the two chambers was a Matrigel matrix that the cancer cells 
can pass through, and the measurement obtained was the percentage of inhibition of chemotaxis 
(cells that did not go through the Matrigel matrix compared to the negative control). Once 
complete the number of cells that migrated was counted. The better inhibitors allowed fewer 
cells to cross the matrix.  
AMD3100 (1000 nM and 62 %)54b, 81, and WZ811 (10 nM and 90 %)63a were used as a 
benchmark to select the best potential antagonists. Compounds that had an inhibition greater than 
50 % were considered favorable and selected for carrageenan paw edema test. Six compounds 
out of the twenty-four achieve this, and a loose trend appears to favor substituents on the ortho 
and para position (Table 1). Four compounds, 2-Chloroaniline, 4-Methoxyaniline, 
Thiomorpholine, and 4-Trifluoromethylbenzylamine, had an inhibition greater than 80 % (2k, 
2p, 2u, and 2v).  
2.2.3 In vivo carrageenan paw edema test 
The mouse paw edema test will be used to determine if these analogs can disrupt the 
CXCR4-CXCL12 interaction in vivo by reducing induced inflammation.54b, 63a This test was 
performed on compounds that did well in the binding affinity, and Matrigel invasion assay. This 
test may also be used to gain some insight into the toxicity of these compounds based on if a 
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mouse becomes weak or dies from the potential antagonist. The results of this test can be seen in 
Table 2. 
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3 RESULTS 
3.1 Assay Results 
Table 1: Results of Matrigel invasion assay, and Binding affinity assay results for all thiophene 
analogs synthesized. The invasion assay concentration used was 100 nM. 
 
Compound EC 
(nM) 
Inhibition 
(%PC) 
R= 
2a 1 68 Aniline (H) 
2b 10 61 2-Methylaniline 
2c >1000 -- 3-Methylaniline 
2d 100 49 4-Methylaniline 
2e 1000 -- 2-Ethylaniline 
2f >1000 -- 3-Ethylaniline 
2g >1000 -- 4-Ethylaniline 
2h 1000 -- 2-Fluoroaniline 
2i >1000 -- 3-Fluoroaniline 
2j >1000 -- 4-Fluoroanilne 
2k 10 93 2-Chloroaniline 
2l 100 51 3-Chloroaniline 
2m 1 22 4-Chloroaniline 
2n 10 52 2-Methoxyaniline 
2o 1000 -- 3-Methoxyanline 
2p 10 84 4-Methoxyaniline 
2q >1000 -- 2-Trifluoromethylaniline 
2r 100 77 3-Trifluoromethylaniline 
2s >1000 -- 4-Trifluoromethylaniline 
2t >1000 -- Morpholine 
2u 1 88 Thiomorpholine 
2v 1 97 4-Trifluoromethylbenzylamine 
2w >1000 -- 3-Fluorobenzylamine 
2x >1000 -- 4-Chlorobenzylamine 
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Table 2: Result of in vivo carrageenan paw edema test. 
Compound % Inhibition SEM (Error bar) R=  
2a 30.36 5.56 Aniline 
2v 22.62 4.78 4-Trifluoromethylbenzylamine 
These three biological evaluations were used to determine the viability of these 
compounds as small molecule CXCR4 antagonists, and to find potential trends for the design and 
synthesis of future compounds. The binding affinity assay was the preliminary screen for potent 
compounds, the Matrigel invasion assay was important to see if our compounds can inhibit 
chemotaxis, and the carrageenan paw edema test gave us an idea of the activity of our compound 
in vivo. From these data, several hit compounds were discovered and selected for carrageenan 
induced paw edema test.  
Eleven of the compounds had a good binding affinity result, and they are listed here from 
best to worst: 2u, 2v, 2m, 2a, 2b, 2p, 2k, 2n, 2d, 2l and finally 2r. Those eleven compounds then 
had their Matrigel invasion results obtained, and they are listed here from best to worst: 2v, 2k, 
2u, 2p, 2r, 2a, 2b, 2n, 2l, 2d, and 2m. Compounds that have a substituent at either the ortho or 
para position tended to be more active in these assays. The final assay indicates that aniline and 
4-Trifluoromethylbenzylamine (2a, and 2v) are currently the best candidates for further analysis. 
The only exceptions are 2a, 2u, 2l, and 2r. The final assay indicates that 2v, and 2a would be 
good candidates for further analysis. 4-Chloroaniline (2k) also needs to be submitted for the 
carrageenan paw edema test.  
4 CONCLUSIONS 
Aniline was one of the best compounds in the carrageeanan mouse paw edema test and gave 
rise to some questions. While 4-Trifluoromethylbenzylamine (2v) had a higher score on the 
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percent inhibition of invasion at 97 % than aniline (2a) at 68 %, aniline was the best compound 
in the carrageenan paw edema test out of the aniline based substituents tested. This leads to the 
idea that the substituents on the aniline yield reduced activity. It is possible that the steric effects 
of the substituents hinder the compound from binding to the active site of CXCR4. This was 
supported by the structure of 4-Trifluoromethylbenzylamine (2v) when compared to other 
anilines, the 4-Trifluorobenzylamine (2v) added an extra carbon between the aromatic phenyl 
ring and the amine which gave it more free rotation so it would be less sterically hindered by the 
phenyl ring. Aniline is less sterically hindered around the phenyl ring when compared to those 
that have substituents on the phenyl ring. 2-Trifluoromethylanilne, 3-Trifluoromethylaniline, and 
4-Trifluoromethylanilne (2q, 2r, and 2s) are only different from the 4-
Trifluoromethylbenzylamine (2v) by having one extra carbon separating the phenyl ring and the 
amine. However, 3-Trifluoromethylaniline (2r) had an EC of 100 nM and 77 % inhibition of 
invasion. This gives credit to the idea that the substituents impart some steric hindrance with the 
binding to the active site, but also potential electronic differences depending on the substituent’s 
position that make the compound better able to bind to the pocket. Molecular docking and more 
benzylamines are needed to confirm if this greater flexibility assists the compound in its binding 
to the active site of CXCR4. Nonaromatic cyclic chains in sizes smaller than aniline could help 
determine if steric hindrance of the amine is a detriment, while chains closer to the size of aniline 
would determine if a lack of steric hindrance in this region would improve binding. Also, 
consider that the phenyl ring was said to be vital to binding. The amines that need to be used to 
further explore the activity of these antagonists include cyclic amines, 
Trifluoromethylbenzylamines, Methylbenzylamines, and Benzylamine. These compounds would 
help in determining how steric and electronic differences affect binding for the Thiophene 
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pharmacophore. The nonaromatic cyclic amines that have already been tried include Morpholine 
(2t), which did not do well, and Thiomorpholine (2u), which had an EC of 1 nM and 88 % 
inhibition of invasion. Thiomorpholine did not have as much steric hindrance as substituted 
anilines, which supports the idea that reducing steric hindrance around those rings is integral. 
Sulfur is bigger than oxygen and less electronegative. Since there is no resonance possible in this 
ring, this one atom difference is what makes this a better compound in the binding affinity assay.    
 When it comes to the aniline based compounds, it is possible that substituents at the three 
position structurally hinder binding to the active site of CXCR4. The Methyl and Methoxy 
substituted compounds, which are electron donating groups bind effectively at the ortho and 
meta position. However, they do not effectively bind to CXCR4 when they are at the meta 
position. The Ethyl substituents, which are even more bulky than the Methyl groups do not do 
well at any position. Likely due to steric effects since methyl has similar electronic effects. 
Fluoro substituted compounds did not do well, and it can be reasoned that the electronic effects 
were the biggest problem since Fluorine is not very bulky. The Trifluoromethyl substituted 
anilines did not do well at the ortho and para position. This is very interesting since at these 
positions the Trifluoromethyl would be a deactivator that would pull electrons away from the 
amine. The 3-Trifluoromethyl substituted aniline (2r) would not pull electrons from the amine as 
much, and it is possible that it would then allow the amine to better interact with the active site. 
The results of the biological evaluations appear to indicate that pulling electrons away from the 
amine of the potential antagonists hinders binding to CXCR4. This is supported by the 2-Methyl 
and 4-Methyl substituted anilines that would donate electrons towards the amine, while the 3-
Methyl would not. This is also true of the methoxy substituted anilines. The Chlorine substituted 
anilines all did well, but the 3-Chloroaniline did the worst. This was likely due to its inductive 
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effects and resonance effects allowing it to do well in all positions. More bulky halogens would 
possibly introduce detrimental steric effects, but would also reduce the electronegativity, which 
may have a good outcome.   
Synthesis of new potential CXCR4 antagonists will continue to create a sufficient library 
from this core. Characterization was accomplished via mass spectrometry and NMR. There are 
binding affinity and Matrigel invasion assays that still need to be completed. The hit compounds 
(2a, and 2v) will also undergo further analysis to determine their suitability as drug candidates. 
Also, compounds that had a Matrigel invasion greater than 50 % will be tested via the paw 
edema test. The trend of the data available indicates that substituents at the ortho and para 
position on the Thiophene core are the best CXCR4 antagonists barring the exceptions 2a, 2l, 2r, 
and 2u. 
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5 EXPERIMENTAL 
Procedure A: To a solution of Thiophene-2,5-dicarboxaldehyde (60 mg, 0.4281 
mmol) in DCE (4.3 mL) was added an amine (2.3 equivalents), and acetic acid (0.05 mL, 
0.8562 mmol) The solution was stirred for 5 min at room temperature, and then treated 
with NaBH(OAc)3 (273 mg, 1.2843 mmol). The solution was then stirred from between 5 
hrs and overnight. The product was then purified via flash column chromatography, or 
preparative thin layer chromatography.  
Procedure B: To a solution of Thiophene-2,5-dicarboxaldehyde (60 mg, 0.4281 
mmol) in Methanol (4.3 mL) was added an amine (2.0-2.3 equivalents). The solution was 
stirred for 1 h at room temperature, and then treated with NaBH4 (48.6 mg, 1.2843). The 
solution was then stirred overnight. The product was then purified via flash column 
chromatography, or preparative thin layer chromatography. 
Procedure C: To a solution of Thiophene-2,5-dicarboxaldehyde (60 mg, 0.4281 
mmol) in Methanol (4.3 mL) was added an amine (2.0 equivalents). The solution as 
stirred 5-10 h under reflux conditions. It was then treated with NaBH4 (48.6 mg, 1.2843 
mmol). The solution as stirred overnight at room temperature. The product was then 
purified via flash column chromatography, or preparative thin layer chromatography. 
The 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were obtained on a 
Bruker Ac 400 FT NMR spectrometer in CDCl3, the Mass spectra were obtained on a 
JEOL spectrometer.  
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2,5-Bis(anilinomethyl)thiophene (2a) This product was obtained in 26 % yield 
as an off white solid; 1H NMR (400 MHz, Chloroform-d) δ 7.17 (t, J = 7.83 Hz, 4H), 
6.83 (s, 2H), 6.73 (t, J = 7.33 Hz, 2H), 6.65 (d, J = 7.83 Hz, 4H), 4.42 (s, 4H); 13C NMR 
(100 MHz, Chloroform-d) δ 147.53, 142.19, 129.26, 124.75, 118.06, 113.12, 43.64; 
Calcd for C18H18N2SNa ([M + H
+]): m/z 317.1087. Found: m/z 317.1088. 
2,5-Bis(2-methylanilinomethyl)thiophene (2b) This product was obtained in 15 
% yield; 1H NMR (400 MHz, Chloroform-d) δ 7.02 - 7.16 (m, 4H), 6.87 (s, 2H), 6.63 - 
6.74 (m, 4H), 4.49 (s, 4H), 2.15 (s, 6H); 13C NMR (100 MHz, Chloroform-d) δ 145.53, 
142.26, 130.15, 127.11, 124.80, 122.28, 117.66, 110.14, 43.66, 17.52; Calcd for 
C20H23N2S ([M + H
+]): m/z 323.1587. Found m/z 323.1576. 
2,5-Bis(3-methylanilinomethyl)thiophene (2c) This product was obtained in 14 
% yield; 1H NMR (400 MHz, Chloroform-d) δ 7.07 (t, J = 7.58 Hz, 2H), 6.83 (s, 2H), 
6.56 (d, J = 7.58 Hz, 2H), 6.39 - 6.52 (m, 4H), 4.42 (s, 4H), 2.27 (s, 6H); 13C NMR (100 
MHz, Chloroform-d) δ 147.59, 142.24, 139.05, 129.14, 124.71, 119.01, 113.94, 110.21, 
43.67, 21.62; Calcd for C20H18N2SNa ([M + H
+]): m/z 345.1391. Found: m/z 345.1401. 
2,5-Bis(4-methylanilinomethyl)thiophene (2d) This product was obtained in 24 
% yield; 1H NMR (400 MHz, Chloroform-d) δ 6.98 (d, J = 8.34 Hz, 4H), 6.81 (s, 2H), 
6.57 (d, J = 8.34 Hz, 4H), 4.39 (s, 4H), 2.23 (s, 6H); 13C NMR (100 MHz, Chloroform-d) 
δ 145.28, 142.34, 129.75, 127.28, 124.61, 113.27, 43.98, 20.42; Calcd for C20H23N2S ([M 
+ H+]): m/z 323.1576. Found: m/z 323.1576. 
2,5-Bis(2-ethylanilinomethyl)thiophene (2e) This product was obtained in 14 % 
yield; 1H NMR (500 MHz, Chloroform-d) δ 7.04 - 7.15 (m, 14H), 6.86 (s, 7H), 6.74 (t, J 
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= 7.34 Hz, 7H), 6.69 (d, J = 8.02 Hz, 7H), 4.48 (s, 4H), 2.49 (q, J = 7.50 Hz, 4H), 1.24 (t, 
J = 7.53 Hz, 16H) ; 13C NMR (100 MHz, Chloroform-d) δ 144.90, 142.33, 127.95, 
126.96, 124.75, 117.84, 110.47, 43.68, 23.88, 12.88; Calcd for C22H25N2S ([M + H
+]): 
m/z 349.1744. Found: m/z 349.1733. 
2,5-Bis(3-ethylanilinomethyl)thiophene (2f) This product was obtained in 18 % 
yield; 1H NMR (400 MHz, Chloroform-d) δ 7.09 (t, J = 7.45 Hz, 7H), 6.83 (br. s., 7H), 
6.60 (d, J = 7.07 Hz, 7H), 6.42 - 6.54 (m, 14H), 4.42 (br. s., 4H), 2.56 (q, J = 7.07 Hz, 
14H), 1.12 - 1.27 (m, 21H); 13C NMR (100 MHz, Chloroform-d) δ 147.63, 145.45, 
142.22, 129.19, 124.73, 117.79, 112.84, 110.38, 43.69, 28.99, 15.51; Calcd for 
C22H27N2S ([M + H
+]): m/z 351.1889. Found: m/z 351.1889. 
2,5-Bis(4-ethylanilinomethyl)thiophene (2g) This product was obtained in 7 % 
yield as a yellow colored solid; 1H NMR (400 MHz, Chloroform-d) δ 7.02 (d, J = 8.34 
Hz, 4H), 6.83 (s, 2H), 6.61 (d, J = 8.34 Hz, 4H), 4.41 (s, 4H), 2.54 (q, J = 7.58 Hz, 4H), 
1.18 (t, J = 7.58 Hz, 6H); 13C NMR (100 MHz, Chloroform-d) δ 145.53, 142.38, 133.93, 
128.58, 124.64, 113.26, 44.01, 27.94, 15.92; Calcd for C22H27N2S ([M + H
+]): m/z 
351.1881. Found: m/z 351.1889. 
2,5-Bis(2-fluoroanilinomethyl)thiophene (2h) This product was obtained in 6 % 
yield as a light yellow oil; 1H NMR (400 MHz, Chloroform-d) δ 6.93 - 7.03 (m, 10H), 
6.86 (s, 5H), 6.71 - 6.79 (m, 5H), 6.66 (dd, J = 3.28, 4.55 Hz, 5H), 4.48 (s, 4H); 13C 
NMR (100 MHz, Chloroform-d) δ 152.74, 150.36, 141.82, 136.01, 135.90, 124.91, 
124.58, 124.54, 117.42, 117.35, 114.61, 114.43, 112.47, 43.23, 29.71;  
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2,5-Bis(3-fluoroanilinomethyl)thiophene (2i) This product was obtained in 3 % 
yield as a yellow oil; 1H NMR (400 MHz, Chloroform-d) δ 7.03 - 7.18 (m, 2H), 6.86 (s, 
2H), 6.42 (d, J = 7.83 Hz, 4H), 6.28 - 6.38 (m, 2H), 4.43 (s, 4H); 13C NMR (100 MHz, 
Chloroform-d) δ 141.74, 130.39, 125.01, 108.93, 104.39, 99.94, 99.69, 43.50, 29.71; 
Calcd for C18H17N2F2S ([M + H
+]): m/z 331.1070. Found: m/z 331.1075. 
2,5-Bis(4-fluoroanilinomethyl)thiophene (2j) This product was obtained in 6 % 
yield as a white solid; 1H NMR (400 MHz, Chloroform-d) δ 6.76 - 6.93 (m, 6H), 6.49 - 
6.63 (m, 4H), 4.36 (s, 4H); 13C NMR (100 MHz, Chloroform-d) δ 157.31, 154.97, 
143.85, 142.14, 124.75, 115.80, 115.58, 114.09, 114.02, 44.26; 
2,5-Bis(2-chloroanilinomethyl)thiophene (2k) This product was obtained in 5 % 
yield as a clear oil; 1H NMR (400 MHz, Chloroform-d) δ 7.22 - 7.31 (m, 3H), 7.12 (t, J = 
7.45 Hz, 2H), 6.87 (br. s., 2H), 6.60 - 6.77 (m, 4H), 4.51 (br. s., 4H); 13C NMR (100 
MHz, Chloroform-d) δ 143.32, 141.63, 129.18, 127.77, 124.90, 119.34, 117.91, 111.59, 
43.27. 
2,5-Bis(3-chloroanilinomethyl)thiophene (2l) This product was obtained in 3 % 
yield; 1H NMR (500 MHz, Chloroform-d) δ 7.08 (t, J = 8.12 Hz, 7H), 6.85 (s, 7H), 6.70 
(d, J = 7.82 Hz, 6H), 6.63 (s, 7H), 6.52 (dd, J = 1.76, 8.22 Hz, 7H), 4.42 (s, 4H); 13C 
NMR (100 MHz, Chloroform-d) δ 148.57, 141.68, 135.03, 130.24, 125.05, 117.96, 
112.79, 111.39, 43.41; Calcd for C18H17N2Cl2S ([M + H
+]): m/z 363.0478. Found: m/z 
363.0484. 
2,5-Bis(4-chloroanilinomethyl)thiophene (2m) This product was obtained in 5 
% yield as a white solid; 1H NMR (400 MHz, Chloroform-d) δ 7.07 - 7.13 (m, 4H), 6.81 
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(s, 2H), 6.51 - 6.57 (m, 4H), 4.38 (s, 4H); 13C NMR (100 MHz, Chloroform-d) δ 145.98, 
141.88, 129.07, 124.85, 122.61, 114.19, 43.64; 
2,5-Bis(2-methoxyanilinomethyl)thiophene (2n) This product was obtained in 7 
% yield; 1H NMR (400 MHz, Chloroform-d) δ 6.82 - 6.90 (m, 4H), 6.75 - 6.81 (m, 2H), 
6.63 - 6.74 (m, 4H), 4.46 (s, 4H), 3.83 (s, 6H); 13C NMR (100 MHz, Chloroform-d) δ 
146.94, 142.20, 137.53, 124.70, 121.23, 117.20, 110.37, 109.56, 55.44, 43.44; Calcd for 
C20H22N2O2SNa ([M + H
+]): m/z 377.1300. Found: m/z 377.1300. 
2,5-Bis(3-methoxyanilinomethyl)thiophene (2o) This product was obtained in 
12 % yield; 1H NMR (400 MHz, Chloroform-d) δ 7.08 (t, J = 8.08 Hz, 2H), 6.83 (s, 2H), 
6.14 - 6.36 (m, 6H), 4.41 (s, 4H), 3.74 (s, 6H); 13C NMR (100 MHz, Chloroform-d) δ 
160.79, 148.90, 142.08, 130.02, 124.83, 106.21, 103.22, 99.21, 55.08, 43.64; Calcd for 
C20H22N2O2SNa ([M + H
+]): m/z 377.1300. Found: m/z 377.1300. 
2,5-Bis(4-methoxyanilinomethyl)thiophene (2p) This product was obtained in 3 
% yield as a light yellow solid; 1H NMR (400 MHz, Chloroform-d) δ 6.75 - 6.85 (m, 6H), 
6.63 (d, J = 8.84 Hz, 4H), 4.39 (s, 4H), 3.74 (s, 6H); 13C NMR (100 MHz, Chloroform-d) 
δ 152.55, 142.41, 141.75, 124.61, 114.86, 114.56, 55.75, 44.66; Calcd for 
C20H22N2O2SNa ([M + H
+]): m/z 377.1300. Found: m/z 377.1300. 
2,5-Bis(2-trifluoromethylanilinomethyl)thiophene (2q) This product was 
obtained in 20 % yield as a clear oil; 1H NMR (400 MHz, Chloroform-d) δ 7.45 (d, J = 
7.58 Hz, 2H), 7.34 (t, J = 7.71 Hz, 2H), 6.85 (s, 2H), 6.70 - 6.81 (m, 4H), 4.77 (br. s., 
2H), 4.51 (d, J = 5.31 Hz, 4H); 13C NMR (100 MHz, Chloroform-d) δ 144.79, 141.32, 
133.10, (126.74, 126.69, 126.63, 126.43), 124.97, 123.72, 116.69, 113.99, 112.20, 43.09; 
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2,5-Bis(3-trifluoromethylanilinomethyl)thiophene (2r) This product was 
obtained in 7 % yield as a clear oil; 1H NMR (400 MHz, Chloroform-d) δ 7.20 - 7.33 (m, 
2H), 6.97 (d, J = 7.83 Hz, 2H), 6.82 - 6.92 (m, 4H), 6.72 - 6.82 (m, 2H), 4.47 (s, 4H), 
4.24 (br. s., 2H); 13C NMR (100 MHz, Chloroform-d) δ 147.59, 141.58, (131.75, 131.44), 
129.71, 125.62, 125.18, 116.03, (114.53, 114.49), (109.37, 109.33), 43.40;  
2,5-Bis(4-trifluoromethylanilinomethyl)thiophene (2s) This product was 
obtained at 6 % yield as a light yellow solid; 1H NMR (400 MHz, Chloroform-d) δ 7.39 
(d, J = 8.59 Hz, 4H), 6.85 (s, 2H), 6.63 (d, J = 8.34 Hz, 4H), 4.25 - 4.61 (m, 6H); 13C 
NMR (100 MHz, Chloroform-d) δ 149.86, 141.56, (126.71, 126.67, 126.64, 126.59), 
126.24, 125.14, 123.55, (120.05, 119.73, 119.41, 119.08), 112.24, 43.09. 
2,5-Bis(morpholinomethyl)thiophene (2t) This product was obtained in 10 % 
yield as an off white/ light yellow solid; 1H NMR (400 MHz, Chloroform-d) δ 6.74 (s, 
2H), 3.68 - 3.77 (m, 8H), 3.66 (s, 4H), 2.49 (br. s., 8H); 13C NMR (100 MHz, 
Chloroform-d) δ 140.76, 125.66, 66.98, 57.80, 53.27; Calcd for C14H23N2O2S ([M + H+]): 
m/z 383.1475. Found: m/z 383.1475. 
2,5-Bis(thiomorpholinomethyl)thiophene (2u) This product was obtained in 6 
% yield as a white solid; 1H NMR (400 MHz, Chloroform-d) δ 6.71 (s, 2H), 3.67 (s, 
15H), 2.61 - 2.84 (m, 59H); 13C NMR (100 MHz, Chloroform-d) δ 141.05, 125.45, 58.18, 
54.57, 28.00; Calcd for C14H23N2S3 ([M + H
+]): m/z 315.1018. Found: m/z 315.1023. 
2,5-Bis(4-trifluoromethyl-1-phenylmethylaminomethyl)thiophene (2v) This 
product was obtained in 16 % yield as a light yellow oil; 1H NMR (500 MHz, 
Chloroform-d) δ 7.58 (d, J = 8.02 Hz, 4H), 7.47 (d, J = 8.02 Hz, 4H), 6.76 (s, 2H), 3.95 
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(s, 4H), 3.89 (s, 18H); 13C NMR (100 MHz, Chloroform-d) δ 144.13, 143.01, 128.36, 
125.36, 125.33, 124.68, 52.16, 47.88; Calcd for C22H21F6N2S ([M + H
+]): m/z 459.1324. 
Found: m/z 459.1324. 
2,5-Bis(3-fluoro-1-phenylmethylaminomethyl)thiophene (2w) This product 
was obtained at 9 % yield as a light yellow oil; 1H NMR (400 MHz, Chloroform-d) δ 
7.23 - 7.33 (m, 2H), 7.04 - 7.15 (m, 4H), 6.88 - 6.99 (m, 2H), 6.76 (s, 2H), 3.94 (s, 4H), 
3.83 (s, 4H); 13C NMR (100 MHz, Chloroform-d) δ 164.24, 161.80, 143.04, 142.77, 
142.70, 129.87, 129.79, 124.62, 123.67, 123.64, 115.04, 114.83, 113.97, 113.76, 52.15, 
47.80; Calcd for C20H20F2N2SNa ([M + H
+]): m/z 381.1207. Found: m/z 281.1213. 
2,5-Bis(4-chloro-1-phenylmethylaminomethyl)thiophene (2x); This product 
was obtained at 3 % yield as a clear oil; 1H NMR (400 MHz, Chloroform-d) δ 7.21 - 7.38 
(m, 8H), 6.75 (s, 2H), 3.93 (s, 4H), 3.80 (s, 4H); 13C NMR (100 MHz, Chloroform-d) δ 
143.04, 138.46, 132.71, 129.53, 128.53, 124.61, 51.96, 47.77; Calcd for C20H20Cl2N2SNa 
([M + H+]): m/z 413.0616. Found: m/z 413.0622. 
5.1.1 Binding affinity assay 
The binding affinity assay is a competitive assay where twenty thousand MDA-MB-231 
breast cancer cells are incubated in an 8-well slide chamber for two days in 300 µL of medium. 
The compounds were also incubated in separate wells at several concentrations (1, 10, 100, 1000 
nM) for ten minutes at room temperature. The cells were then fixed in a chilled solution of 4 % 
paraformaldehyde. After the cells were rehydrated in phosphate-buffered saline (PBS), the slides 
were prepared by incubating them with 0.05 µg/mL biotinylated TN14003 for thirty minutes at 
room temperature. These slides were washed three times with the PBS solution and were then 
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incubated for thirty minutes at room temperature in streptavidin-rhodamine (1:150 dilution; 
Jackson ImmunoResearch Laboratories, West Grove, PA). The slides were washed again with 
the PBS solution and were mounted in an antifade mounting solution (Molecular Probes, 
Eugene, OR). A Nikon Eclipse E800 microscope was used to analyze the samples63a, 82.  
5.1.2 Matrigel invasion assay 
This assay was performed using a Matrigel invasion chamber (Corning Biocoat;Bedford, 
MA). In the bottom chamber, a solution of CXCL12 (100 ng/mL; R&D Systems, Minneapolis, 
MN) was added to the apparatus. 100 nm of the selected compounds (or AMD3100 as a control) 
were added to the MDA-MB-231. The cells were then placed in the top chamber. The apparatus 
was then incubated in a humidified incubator for 22 hours. The remaining cells in the top 
chamber were removed using a cotton swab and the invading cells in the bottom chamber were 
stained hematoxylin and eosin (H&E) and fixed with methanol. The rate of invasion was 
calculated by counting the invading (stained) cells63a, 82.  
5.1.3 Paw inflammation test 
In this test, C57BL/6J does (Jackson Laboratories) are subcutaneously injected with λ-
carrageenan (50 μL in 1 % w/v in saline) in the right hind paw to trigger inflammation; the other 
hind paw is used as the non-inflammation control. The selected analogues were prepared in 10 % 
DMSO and 90 % of 45% (2-hydroxypropyl-β-cyclodextrin (CD) in PBS. Doses of the analogues 
were set at 10 mg/kg and the does for TN14003 was set at 300 μg/kg. The TN14003 dose was set 
lower for this experiment because it was found that 300 μg/kg gave the maximum efficacy at 
minimum concentration in breast cancer metastasis in an animal model. The mice were dosed 30 
minutes after the carrageenan injection and then once a day following the initial dose. The mice 
were sacrificed 74 hours after inflammation was induced and two hours after the last injection of 
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the selected analogues. The hind paws of the mice were photographed and calipers were used to 
measure the thickness of the paw from front to back. To quantify the edema, the volume of the 
untreated paw was subtracted from the volume of the treated paw. The inflammation suppression 
percentage was determined by comparing the analogue treated groups to the control group. Each 
analogue was tested in quintuplicate using the above procedure54b, 63a. Paw tissue slices were also 
collected and stained with H&E. Tissue slices were scanned and digitized by NanoZoomer 2.0 
HT. The software NDP.view2 was used to view the slices in detail.  
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